Abbott Closes $60B Exact Sciences Deal, Bolsters Cancer Diagnostics
Event summary
- Abbott completes $60B acquisition of Exact Sciences on March 23, 2026.
- Exact Sciences adds $3B in incremental sales for Abbott in 2026.
- Deal accelerates Abbott's 2026 sales growth by 0.5%, dilutes EPS by $0.20.
- Exact Sciences' portfolio includes Cologuard, Oncotype DX, Oncodetect, and Cancerguard.
- Abbott gains leadership in fast-growing $60B U.S. cancer screening and precision oncology diagnostics segments.
The big picture
Abbott's acquisition of Exact Sciences positions it as a leader in the fast-growing cancer diagnostics market, addressing rising global cancer incidence. The deal expands Abbott's diagnostic capabilities into preventative, predictive, and personalized technologies, aligning with broader industry trends toward early cancer detection and precision medicine. With Exact Sciences' portfolio, Abbott gains a significant foothold in the $60B U.S. cancer screening and precision oncology diagnostics segments, enhancing its growth profile and diagnostic leadership.
What we're watching
- Integration Challenges
- How Abbott will integrate Exact Sciences' operations and realize anticipated synergies.
- Market Leadership
- Whether Abbott can sustain its leadership in the fast-growing cancer diagnostics segment.
- Regulatory Risks
- The pace at which regulatory actions or litigation could impact the deal's outcomes.
Related topics